Breaking News from Maui Derm 2024: Bimekizumab Shows Maintenance of Response in HS
Bimekizumab demonstrated sustained response in hidradenitis suppurativa (HS), according to a late breaker presented at Maui Derm 2024. Almost all patients who responded after an initial 16 weeks of bimekizumab treatment maintained HiSCR50 (Hidradenitis Suppurativa Clinical Response) and AN count of 0, 1, or 2 clinical response rates through Wk48, the study showed. Bimekizumab, a […]